Last Updated： Aggregation Period:Sep 17, 2025～Oct 14, 2025
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Sep 17, 2025～Oct 14, 2025
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Sep 17, 2025～Oct 14, 2025
This ranking is based on the number of page views on our site.
46～60 item / All 585 items
Measures from low range "LR" 0.02 to 2 mg/L and high range "HR" 0.2 to 30 mg/L.
We offer a total phosphorus test reagent based on the measurement principle of spectrophotometry (molybdenum blue method). The measurement ranges are low range "LR" 0.02 to 2 mg/L and high range "HR" 0.2 to 30 mg/L, with a processing time of 30 minutes at 125°C. *For more details, please download the PDF or contact us.
We can develop various new drugs that are not limited to specific diseases or target proteins.
Our core drug discovery technology, the "RiboART (Ribomic Aptamer Refined Therapeutics) System," is built on comprehensive technologies, knowledge, and experience related to aptamer drug discovery, establishing a platform (drug discovery foundation) that can be universally applied to the creation of new drug candidates. By using the "RiboART System," it is possible to develop various new drugs that are not limited to specific diseases or target proteins. Please feel free to contact us if you have any inquiries. 【Features of Aptamer Pharmaceuticals】 ■ Strong target binding ability ■ Few restrictions on targets ■ Easy chemical modifications ■ Production through chemical synthesis ■ Low antigenicity *For more details, please download the PDF or contact us.
Process optimization is possible! We propose a balanced active pharmaceutical ingredient development plan that considers speed, cost-effectiveness, and quality.
We would like to introduce our pharmaceutical active ingredient division (Pharmaceutical Research Headquarters) and its business and technology. We flexibly utilize a network of reliable partner contract manufacturers to build and propose an optimal active ingredient manufacturing supply chain tailored to specific purposes. With world-class pharmaceutical development technology and assured quality, we provide "the development of active ingredient manufacturing methods from 'zero' that meet global application requirements" and "a seamless and consistent active ingredient manufacturing process and quality design from preclinical stages to obtaining marketing approval." 【Features】 ■ Development of active ingredient manufacturing methods from 'zero' based on technology and know-how cultivated over many years at major domestic pharmaceutical companies. ■ Establishment of active ingredient manufacturing methods and quality design according to development stages and applications. ■ Flexible response to active ingredient manufacturing requests. ■ Accurate support for application processes (clinical trials and commercial use). *For more details, please refer to the PDF materials or feel free to contact us.
![[Technology and Achievements Introduction] Absorption Improvement Technology (Nanosized Formulation)](https://image.mono.ipros.com/public/product/image/ce6/2000706996/IPROS80210347929226024498.png?w=280&h=280)
Introducing the correlation diagram of particle size and surface area! It is applied to investigational drugs targeting compounds in the development stage.
We would like to introduce Spela Pharma's "Absorption Improvement Technology." By using nano-sized active pharmaceutical ingredients, we enhance bioavailability. We have successfully developed formulations using this technology and are applying it to investigational drugs targeting compounds in the development stage. On our website, we provide a correlation chart of particle size and surface area, as well as graphs showing plasma concentration in dogs for nano-particles and jet-milled active pharmaceutical ingredients, so please check the related links below. [Features] ■ Improved bioavailability through nano-sized active pharmaceutical ingredients ■ Successful development of formulations using this technology ■ Application to investigational drugs targeting compounds in the development stage *For more details, please refer to the PDF materials or feel free to contact us.
![[Thank You] CPhI Japan 2022](https://image.mono.ipros.com/public/product/image/695/2000710295/IPROS60334295366830476152.png?w=280&h=280)
Thank you for attending CPhI Japan 2022 (International Pharmaceutical Development Exhibition)!
Sperafarma exhibited at CPhI Japan 2022 (International Pharmaceutical Development Exhibition, April 20-22, Tokyo Big Sight) and welcomed many customers to our booth. As a CDMO capable of providing a wide range of services from early-stage R&D to the manufacturing of clinical trial drugs, commercial manufacturing, and raw material procurement, we will accelerate our support for pharmaceutical development. We would like to express our gratitude to everyone who provided us with opportunities for exchanging opinions and sharing information. 【Overview of Presentations at the Booth】 ■ Screening technologies required in active pharmaceutical ingredient research - catalyst selection, crystallization - ■ Mutagenic impurities in pharmaceuticals (active pharmaceutical ingredients) - development of testing methods and analysis examples - *For more details, please refer to the PDF materials or feel free to contact us.
Next-generation antibody and peptide aptamer drug discovery business!
Our company is engaged in drug discovery business for next-generation antibodies and peptide aptamers through in-house research, joint research, and alliances. Under the NEDO Research and Development Venture Support Program (STS) for the fiscal year 2017, we successfully automated the "genotype/phenotype molecular matching technology," one of the evolving molecular engineering technologies, enabling the automated preparation of a homogeneous cDNA display library with a diversity of 10^14 (hundreds of trillions). In addition to the naive VHH gene library through a technical partnership with RePHAGEN, we also possess a high-quality peptide gene library in-house. *For more details, please contact us.
![[Research Material] Global Market for Antimicrobial Treatment](https://image.mono.ipros.com/public/product/image/e90/2000826656/IPROS54989891873130249587.jpeg?w=280&h=280)
Global Market for Antimicrobial Therapy: Penicillin, Cephalosporins, Quinolones, Aminoglycosides, Monobactams, Carbapenems, Macrolides, ...
This research report (Global Antibacterial Therapeutic Market) investigates and analyzes the current state of the global antibacterial therapeutic market and its outlook for the next five years. It includes information on the overview of the global antibacterial therapeutic market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The segments by type in the antibacterial therapeutic market include penicillin, cephalosporins, quinolones, aminoglycosides, monobactams, carbapenems, macrolides, and others, while the segments by application cover oral, topical, non-oral, and others. The regional segments are classified into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa to calculate the market size for antibacterial therapeutics. It also includes the market share of major companies in antibacterial therapeutics, product and business overviews, and sales performance.
![[Market Report] Global Market for Hemophilia Treatment](https://image.mono.ipros.com/public/product/image/4bd/2000925711/IPROS88080425648458218293.jpeg?w=280&h=280)
World Market for Hemophilia Treatment: Advances in medical therapies that enhance patient quality of life in the management of this rare bleeding disorder.
The global hemophilia treatment market is making significant progress as advancements in medical therapies innovate the management of this rare bleeding disorder. Hemophilia is a condition caused by genetic factors that impairs the blood's ability to clot properly, leading to prolonged bleeding times and an increased risk of severe bleeding symptoms. However, the emergence of innovative treatments has allowed patients to experience improved outcomes and enhanced quality of life. According to the latest market report, the global hemophilia treatment market reached $12.8 billion in 2021, with a steady growth forecast of a compound annual growth rate (CAGR) of 6.3% from 2022 to 2030. You can check the application method by clicking the [PDF Download] button or apply directly through the related links.
Keywords: glycan, antibody, molecular recognition, multivalent effect, detection reagent
The proverb "When three people gather, the wisdom of Monju" is often heard in our daily lives. Did you know that the power of groups exists even at the molecular level? Glycans facilitate intercellular communication by binding to glycan receptors, but individual glycans have only weak binding strength. However, when multiple glycans come together, their effect far exceeds simple addition, sometimes exhibiting astonishing powers that can be hundreds to hundreds of thousands of times greater. This is called the "multivalency effect." The characteristic of our research is to artificially replicate and further enhance this clever mechanism found in nature. We design artificial molecules that accumulate various molecules, such as glycans and next-generation antibodies, and investigate their interactions in detail. By effectively utilizing the power of molecular cooperation, we hope to contribute to the future of medicine.
What should be considered to understand process chemistry and establish an effective manufacturing method compliant with GMP? Efforts in the lab? Scale-down.
Lecturer Representative Director of Pharmaceutical Research and Development Consulting, Mr. Mitsuki Hashimoto Target Audience: Individuals responsible for process chemistry in pharmaceutical development facing challenges Venue: Kawasaki City Educational and Cultural Center, Room 3 [Kanagawa, Kawasaki] 12 minutes on foot from JR Kawasaki Station, 10 minutes on foot from Keikyu Kawasaki Station Date and Time: April 27, 2011 (Wednesday) 10:30 AM - 4:00 PM [Individual Consultation: 4:00 PM - 4:30 PM (Reservation required)] Capacity: 30 people *Registration will close once full. Please apply early.
If you are in Meguro Ward, please consult Takumi Tax Accountant Office.
If you are looking for a tax accountant strong in manufacturing and construction industries, please consult Takumi Tax Accountant Office in Meguro Ward. We specialize in financial support from fundraising to achieving profitability.
![[Knowledge of Traditional Chinese Medicine] Basic Functions of Herbal Medicine (3) 'Rising, Falling, Floating, Sinking'](https://image.mono.ipros.com/public/product/image/ef4/2000440336/IPROS17158014524038684684.jpg?w=280&h=280)
Introducing knowledge of traditional Chinese medicine! This explains the basic actions of herbal medicine: "ascend, descend, float, and sink."
In traditional Chinese medicine, "Shō" refers to upward symptoms such as vomiting, hiccups, and asthma; "Kō" refers to downward symptoms such as prolapse, urinary incontinence, and excessive menstruation; "Fu" refers to outward symptoms such as night sweats; and "Chin" refers to inward symptoms that have not been resolved on the surface and have penetrated deeper (for example, a cold that has worsened from an infection near the surface to affecting the internal organs). Medicines also have four different directional actions: ascending, descending, floating, and sinking. By administering medicines with the appropriate directional action according to the symptoms, we can alleviate symptoms and improve the illness. [Key Points] ■ Medicines have four different directional actions. ■ Administering medicines with the appropriate directional action according to the symptoms can alleviate symptoms and improve the illness. *For more details, please refer to the PDF document or feel free to contact us.
RBM-007 is considered a potential new treatment for wet AMD patients with no prior treatment history!
We would like to introduce the clinical trials conducted by our company. As a clinical trial targeting exudative age-related macular degeneration (wet AMD), a Phase 2 clinical trial was conducted in the United States after the implementation of a Phase 1/2a clinical trial, aimed at confirming the clinical proof of concept (POC) of multiple administrations of RBM-007. Furthermore, a physician-led clinical trial was conducted in the United States to evaluate the efficacy and safety of RBM-007 monotherapy in treatment-naive wet AMD patients. 【Main Trials】 ■ Randomized double-blind trial ■ Open-label trial ■ Physician-led clinical trial *For more details, please refer to the PDF materials or feel free to contact us.
RBM-007 strongly suggests that it could be a new drug for cartilage dysplasia!
We would like to introduce the clinical trials conducted by our company. The project concerning achondroplasia received support from the Japan Agency for Medical Research and Development (AMED) and began a Phase 1 trial in July 2020 at a domestic clinical trial facility to investigate the safety, tolerability, and pharmacokinetics of RBM-007, which was conducted until May 2021. Regarding the Phase 2 trial of this project, it has been adopted as a pre-commercialization support project for orphan drugs by AMED for three years starting from the fiscal year 2021. [Main Trials] ■ Phase 1 Clinical Trial ■ Early Phase 2 Observational Trial ■ Early Phase 2 Clinical Trial ■ Early Phase 2 Long-term Clinical Trial *For more details, please refer to the PDF materials or feel free to contact us.
Thorough explanation of causes and countermeasures!
As it gets cold during this time of year, some people may find themselves feeling down, saying things like "I just feel gloomy" or "I have no motivation to do anything..." This might be what is known as "winter blues." It has symptoms similar to depression and is more likely to occur in winter, which is why it is also called "seasonal affective disorder." In this article, we will explain in detail the symptoms, causes, and ways to improve "winter blues." *You can read the continuation of the article through the related link (our company website).
